Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026

Reuters2026/08/17 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amylyx scheduled topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia on Aug. 18, 2026.
Results have not been presented yet; management plans an 8:00 a.m. ET conference call with an audio webcast.
The update is expected to clarify whether avexitide can meaningfully reduce hypoglycemia episodes in this patient group.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608171601BIZWIRE_USPR_____20260817_BW660841) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026

You may also like

Crypto prices